Submission of Annual Secretarial Compliance Report for the Year ended 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has informed BSE that it is not required to file the Annual Secretarial Compliance Report for the financial year ended 31 March 2025. The company is citing Regulation 15(2)(b) of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations 2015, which exempts listed entities whose paid-up capital does not exceed Rs. 10 crore and net worth does not exceed Rs. 25 crore. The company states that its paid-up capital and turnover fall below the prescribed threshold limits, making the regulation non-applicable to it. The letter was signed by Director Venkata Rao Sadhanala (DIN: 02906370) on May 5, 2025.
This is a routine compliance disclosure with no material impact on shareholders or the stock price. It simply confirms that Venmax qualifies as a small-cap listed entity exempt from a specific corporate governance filing requirement.